Extrahepatic 90Y Complication; Gastric Ulcer Secondary to 90Y Therapy for Liver Metastasis Despite Negative Preprocedural Imaging
- PMID: 38510819
- PMCID: PMC10948730
- DOI: 10.1007/s13139-023-00828-z
Extrahepatic 90Y Complication; Gastric Ulcer Secondary to 90Y Therapy for Liver Metastasis Despite Negative Preprocedural Imaging
Abstract
Transarterial radioembolization using yttrium-90 (90Y) therapy has become a standard modality of treatment for primary and metastatic liver malignancies due to its high efficacy rate and relatively low risk of adverse effects compared to other forms of locoregional and systemic therapies. Non-target distribution of radio embolic beads and adjacent structure radiation are the two most common adverse effects. However, these are rarely encountered due to thorough imaging and mapping studies prior to 90Y therapy. We present the case of a 66-year-old male who developed a radiation-induced gastric ulcer following 90Y therapy with negative pre-procedural imaging and mapping who was retrospectively found to have an accessory artery from the left hepatic artery to the gastric antrum.
Keywords: 90Y TheraSphere; Non-target distribution; Pre-procedural imaging; Radiation ulcer; Transarterial radioembolization (TARE).
© The Author(s), under exclusive licence to Korean Society of Nuclear Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Competing InterestsThe authors declare no competing interests.Conflict of InterestsConnor Shea, Hannah Lamberg, Sevcan Turk, Mamadou Sanogo, Danielle Turgeon, Broko Nojkov, Kirk Frey and David Raffel declare no competing interests.
Similar articles
-
Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2038-44. doi: 10.1007/s00259-015-3122-6. Epub 2015 Jul 21. Eur J Nucl Med Mol Imaging. 2015. PMID: 26194715
-
Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy.Nucl Med Commun. 2016 Sep;37(9):917-23. doi: 10.1097/MNM.0000000000000544. Nucl Med Commun. 2016. PMID: 27182686
-
Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT.Cardiovasc Intervent Radiol. 2020 Feb;43(2):295-301. doi: 10.1007/s00270-019-02198-6. Epub 2019 Oct 2. Cardiovasc Intervent Radiol. 2020. PMID: 31578635
-
Locoregional Therapies of Cholangiocarcinoma.Visc Med. 2016 Dec;32(6):414-420. doi: 10.1159/000453010. Epub 2016 Dec 5. Visc Med. 2016. PMID: 28229076 Free PMC article. Review.
-
Yttrium-90 Microspheres for Intermediate- or Advanced-Stage Hepatocellular Carcinoma [Internet].Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Mar. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Mar. PMID: 34191460 Free Books & Documents. Review.
References
-
- Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu R, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507.e2. doi: 10.1053/j.gastro.2010.10.049. - DOI - PMC - PubMed